U
Ulrich Göbel
Researcher at University of Düsseldorf
Publications - 383
Citations - 13793
Ulrich Göbel is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Germ cell tumors & Chemotherapy. The author has an hindex of 54, co-authored 379 publications receiving 12956 citations. Previous affiliations of Ulrich Göbel include University of Turin.
Papers
More filters
Journal ArticleDOI
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation
TL;DR: It is shown that human MSCs express IDO protein and exhibit functional IDO activity upon stimulation with IFN-gamma, identifying IDO-mediated tryptophan catabolism as a novel T-cell inhibitory effector mechanism in human M SCs.
Journal ArticleDOI
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Beate Kempf-Bielack,Stefan S. Bielack,Heribert Jürgens,Detlev Branscheid,Wolfgang E. Berdel,G. Ulrich Exner,Ulrich Göbel,Knut Helmke,Gernot Jundt,Hartmut Kabisch,Mathias Kevric,Thomas Klingebiel,Rainer Kotz,Rainer Maas,Rudolf Schwarz,Michael Semik,Jörn Treuner,Andreas Zoubek,Kurt Winkler +18 more
TL;DR: Time to relapse and tumor burden correlate with postrelapse outcome in osteosarcoma and Chemotherapy, particularly chemotherapy with more than one agent, may contribute to limited improvements in outcome.
Journal ArticleDOI
Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial.
Herbert Jürgens,Ulrich Exner,Helmut Gadner,Dieter Harms,Jörg Michaelis,Rolf Sauer,Jörn Treuner,Tom Voûte,Winfried Winkelmann,Kurt Winkler,Ulrich Göbel +10 more
TL;DR: Tumor load and responsiveness to chemotherapy are the two major factors influencing prognosis in patients with primary Ewing's sarcoma of bone.
Journal ArticleDOI
Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
M. Paulussen,S. Ahrens,Juergen Dunst,W. Winkelmann,G. U. Exner,Rainer Kotz,Gabriele Amann,Barbara Dockhorn-Dworniczak,D. Harms,St. Müller-Weihrich,Karl Welte,B. Kornhuber,Gritta Janka-Schaub,Ulrich Göbel,Jörn Treuner,P. A. Voûte,Andreas Zoubek,Helmut Gadner,Heribert Jürgens +18 more
TL;DR: Fifty-two percent of CESS 86 patients survived after risk-adapted therapy, and high-risk patients seem to have benefited from intensified treatment that incorporated ifosfamide, in multivariate analyses.
Journal ArticleDOI
Neonatal symptomatic thromboembolism in Germany: two year survey
TL;DR: Controlled multicentre studies are needed to obtain more information on treatment efficacy of diagnostic imaging techniques and therapeutic modalities in neonates with symptomatic neonatal thromboembolism in Germany.